Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT00075387 : Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
PhasePhase 2
AgesMin: 18 Years Max: 75 Years
Eligibility
Inclusion Criteria:

- Subjects with histologically confirmed high-grade glioma are eligible; diagnosis of
high-grade glioma will be made on the basis of needle biopsy, open biopsy, or surgical
resection

- Subjects may have had prior focal or systemic radiation or chemotherapy; at least 14
days must have elapsed since radiation treatment and 28 days since prior chemotherapy

- Performance status (Eastern Cooperative Oncology Group [ECOG]) must be less than or
equal to 2 (Karnofsky greater than or equal to 50)

- White blood cell count >= 2.5 x 10^3/mm^3

- Absolute granulocyte count >= 1.2 x 10^3/mm^3

- Platelets >= 100 x 10^3/mm^3

- Creatinine < 1.8

- Bilirubin < 2.0

- Baseline aspartate aminotransferase (AST)/alanine aminotransferase (ALT) serum
glutamic oxaloacetic transaminase (SGOT)/serum glutamate pyruvate transaminase (SGPT)
must be < 2.5 x institutional upper limits of normal

- Subject (or legal guardian) must sign a written informed consent in accordance with
institutional guidelines

- Sexually active women of child-bearing potential and men must agree to use adequate
contraception (hormonal or barrier method of birth control; or abstinence) prior to
study treatment and for the duration of study treatment; should a female become
pregnant or suspect she is pregnant while participating in this study, she should
inform the investigator

Exclusion Criteria:

- Subjects with rapidly progressing central nervous system (CNS) disease with associated
neurological deterioration

- Subjects with uncontrolled (over the last 30 days) clinically significant confounding
medical conditions such as congestive heart failure

- Subjects who are pregnant, have a positive serum human chorionic gonadotropin (hCG) or
are lactating

- Subjects who have contraindications to carboplatin, cyclophosphamide, etoposide
phosphate, or sodium thiosulfate
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT00075387      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740